论文部分内容阅读
目的:观察肝康片对化学药物诱发肝损伤的保护作用。方法:将60只昆明小鼠随机分成6组:正常对照组、模型组、肝康片高、中、低剂量组(32.8,16.4,8.2 g.kg-1)和护肝片组(5.62 g.kg-1)。除正常组和模型组外,其余小鼠每日给药ig 1次,共7 d,从第5天开始,各给药组及模型组予ip 0.2%CCl4(20 mL.kg-1)1次,造成急性肝损伤。造模后48 h,采血测定血清中天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)含量。另取60只SD大鼠,随机分成6组:正常对照组、模型组、肝康片高、中、低剂量组(22.68,11.34,5.67 g.kg-1)和护肝片组(3.8 g.kg-1),除正常组ip等体积生理盐水外,其他大鼠ip 10%CCl4(5 mL.kg-1),每周2次,连续7周,造成慢性肝损伤。观察大鼠血清的生化指标和病理组织变化。结果:给药7 d,肝康片高中剂量组可降低小鼠CCl4急性肝损伤血清中的ALT(47.31±9.37),(60.14±11.25)U.L-1和AST(231.67±19.26),(272.11±15.25)U.L-1含量,与模型组比较均有显著的差异。给药8周,各剂量组肝康片还可明显降低CCl4大鼠慢性肝损伤血清中ALT和AST的含量,提高血清中的白蛋白(ALB)(40.7±1.5),(39.6±1.8)g.L-1的含量,降低血清中总胆红素(TBIL)(9.22±1.90),(9.34±2.78)μmol.L-1的含量,与模型组比较均有显著差异。结论:肝康片对CCl4所致小鼠急性肝损伤和大鼠慢性肝损伤均有明显的治疗作用。
Objective: To observe the protective effect of Gankang tablet on liver injury induced by chemical drugs. Methods: Sixty Kunming mice were randomly divided into 6 groups: normal control group, model group, high, medium and low doses of GKT, 32.8,16.4 and 8.2 g.kg-1, .kg-1). Except the normal group and the model group, the other mice were administered with ig once a day for 7 days. From the 5th day, the other groups were given ip 0.2% CCl4 (20 mL.kg-1) 1 Times, resulting in acute liver injury. 48 h after modeling, blood was collected for the determination of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Sixty Sprague-Dawley rats were randomly divided into 6 groups: normal control group, model group, high, medium and low doses of GKG (22.68, 11.34, 5.67 g.kg-1) .kg-1), except for the normal group ip volume of saline, ip 10% CCl4 (5 mL.kg-1) other rats, twice a week for 7 weeks, causing chronic liver injury. Serum biochemical markers and pathological changes were observed. RESULTS: After 7 days of administration, GKDH group could reduce ALT (47.31 ± 9.37), (60.14 ± 11.25), UL-1 and AST (231.67 ± 19.26) and (272.11 ± 15.25) UL-1 content, compared with the model group were significantly different. After 8 weeks of administration, Gankang tablets of each dose group could significantly reduce the levels of ALT and AST in the serum of CCl4-induced chronic liver injury and increase the levels of serum albumin (ALB) (40.7 ± 1.5), (39.6 ± 1.8) gL -1, and decreased the level of total bilirubin (TBIL) (9.22 ± 1.90) and (9.34 ± 2.78) μmol.L-1 in serum, which were significantly different from the model group. Conclusion: Gankang tablet has a significant therapeutic effect on CCl4-induced acute liver injury and chronic liver injury in rats.